Mydayis Dosing Guide
For patients 13 years and older with ADHD, start Mydayis at 12.5 mg once daily upon awakening, titrate weekly by 12.5 mg increments based on response and tolerability, with a maximum dose of 25 mg/day for adolescents (13-17 years) and 50 mg/day for adults. 1
Starting Dose and Administration
- Initial dose: 12.5 mg once daily for both adults and adolescents (13-17 years) 1
- Administer upon awakening because effects last up to 16 hours and can cause insomnia if taken later 1
- Take consistently either with or without food (choose one approach and maintain it) 1
- Do not substitute Mydayis for other amphetamine products on a milligram-per-milligram basis due to different amphetamine base compositions and pharmacokinetic profiles 1
Titration Schedule
Increase by 12.5 mg weekly if symptom control is inadequate and the medication is well-tolerated 1. This aligns with general amphetamine titration principles of increasing by 2.5-5 mg for immediate-release formulations 2, scaled appropriately for this extended-release product.
Monitor response using:
- ADHD rating scales from parents and teachers (for adolescents)
- Self-ratings and functional assessments (for adults)
- Target symptom improvement at school, work, and home 2
Maximum Doses
Dose Adjustments for Renal Impairment
- Severe renal impairment (adults): Maximum 25 mg/day 1
- Severe renal impairment (adolescents): Maximum 12.5 mg/day 1
- End-stage renal disease (ESRD): Not recommended for any age group 1
Pre-Treatment Assessment
Before initiating Mydayis, assess for:
- Cardiac disease: Obtain history of structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease 1
- Baseline vital signs: Blood pressure, pulse, height, and weight 2
- Substance use history: Screen adolescents and adults for active substance use; if present, refer to subspecialist before starting stimulants 3
- Psychiatric conditions: Screen for risk factors for mania, active psychosis, or severe anxiety 1
- Family history: Assess for tics or Tourette's syndrome 1
Absolute Contraindications
Do not prescribe Mydayis if the patient has: 2, 1
- Known hypersensitivity to amphetamine products
- Current or recent (within 14 days) monoamine oxidase inhibitor use
- Symptomatic cardiovascular disease, including structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or coronary artery disease
- Active psychotic disorder
- Glaucoma
- Hyperthyroidism
- Moderate to severe hypertension
Monitoring Schedule
Initial Titration Phase (Weeks 1-4)
- Weekly contact (office visit or phone) to assess response and side effects 2
- Collect ADHD rating scales from multiple informants
- Monitor for common adverse effects: decreased appetite, insomnia, headache, abdominal pain 1
Maintenance Phase
- Monthly visits until symptoms stabilize 2
- Quarterly thereafter for stable patients
- At each visit: Check blood pressure, pulse, weight 2
- Annual height measurements for adolescents to monitor growth 3
Common Pitfalls to Avoid
Underdosing: Community practice often uses lower doses than clinical trials 4. If symptoms persist at lower doses, continue titrating to maximum recommended dose before switching medications 2
Inadequate trial duration: Allow at least one week at each dose level to assess response 2
Ignoring diversion risk: Adolescents are at higher risk for medication diversion. Monitor prescription refill patterns and consider checking prescription drug monitoring programs 3
Late-day dosing: Administering Mydayis after morning hours increases insomnia risk given its 16-hour duration of action 1
Substitution errors: Mydayis has different pharmacokinetics than other amphetamine products; do not convert doses directly from other formulations 1
Special Considerations for Adolescents
- Driving coverage: Ensure medication provides symptom control during driving hours, as adolescents with ADHD have increased crash risk 3
- School performance: Mydayis's extended duration (up to 16 hours) provides coverage through after-school homework periods 1
- Growth monitoring: Track height and weight at each visit; consider drug holidays if growth suppression occurs 3